Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.65 |
| ▸ | BCR | P11274 | 3/20 | 0.65 |
| ▸ | PRKCA | P17252 | 3/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 8/20 | 0.61 |
| ▸ | CDK4 | P11802 | 7/20 | 0.61 |
| ▸ | GSK3B | P49841 | 3/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.61 |
| ▸ | CDK9 | P50750 | 5/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.56 |
| ▸ | CDK1 | P06493 | 2/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.56 |
| ▸ | CDK7 | P50613 | 2/20 | 0.56 |
| ▸ | CCNH | P51946 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617309 | 0.88 | PIK3CA (0.64) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL4733401 | 0.82 | ABL1 (0.60) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL4733655 | 0.81 | PIK3CG (0.76) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL3609139 | 0.81 | PIK3CG (0.55) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL4736155 | 0.80 | ABL1 (0.71) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL3596098 | 0.80 | CDK9 (0.76) | ABL1CDK2CDK4GSK3BSLC2A1 | |
| SCHEMBL3614099 | 0.80 | ABL1 (0.63) | ABL1BCRPRKCASRCGSK3B | |
| SCHEMBL3598695 | 0.80 | JAK2 (0.56) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL4734534 | 0.79 | ABL1 (0.68) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL3607096 | 0.79 | CDK9 (0.62) | ABL1CDK2GSK3BSLC2A1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071774-B2 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-01-14 | — | — | US | disclosed |
| EP-1896481-A2 | HETEROCYCLIC SPIRO-COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | Speedel Experimenta AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006128852-A2 | HETEROCYCLIC SPIRO-COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ABL1 3215/4885BCR 3115/4885PRKCA 4612/4885 |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | REN, NR3C2, CYP21A2 | ABL1 4392/4885BCR 3687/4885PRKCA 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.